Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

P. J. Meunier, C. Roux, S. Ortolani, M. Diaz-Curiel, J. Compston, P. Marquis, C. Cormier, G. Isaia, J. Badurski, J. D. Wark, J. Collette, J. Y. Reginster

Research output: Contribution to journalArticle

Abstract

Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. Introduction: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. Methods: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. Results: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction∈= ∈0.67, p∈

Original languageEnglish
Pages (from-to)1663-1673
Number of pages11
JournalOsteoporosis International
Volume20
Issue number10
DOIs
Publication statusPublished - Oct 2009

Fingerprint

strontium ranelate
Osteoporosis
Therapeutics
Placebos
Quality of Life
Bone and Bones
Osteoporotic Fractures
Risk Reduction Behavior
Bone Density
Morbidity
Safety

Keywords

  • Bone densitometry
  • Menopause
  • Osteoporosis treatment
  • Osteoporotic fracture
  • Strontium ranelate

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. / Meunier, P. J.; Roux, C.; Ortolani, S.; Diaz-Curiel, M.; Compston, J.; Marquis, P.; Cormier, C.; Isaia, G.; Badurski, J.; Wark, J. D.; Collette, J.; Reginster, J. Y.

In: Osteoporosis International, Vol. 20, No. 10, 10.2009, p. 1663-1673.

Research output: Contribution to journalArticle

Meunier, PJ, Roux, C, Ortolani, S, Diaz-Curiel, M, Compston, J, Marquis, P, Cormier, C, Isaia, G, Badurski, J, Wark, JD, Collette, J & Reginster, JY 2009, 'Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis', Osteoporosis International, vol. 20, no. 10, pp. 1663-1673. https://doi.org/10.1007/s00198-008-0825-6
Meunier, P. J. ; Roux, C. ; Ortolani, S. ; Diaz-Curiel, M. ; Compston, J. ; Marquis, P. ; Cormier, C. ; Isaia, G. ; Badurski, J. ; Wark, J. D. ; Collette, J. ; Reginster, J. Y. / Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. In: Osteoporosis International. 2009 ; Vol. 20, No. 10. pp. 1663-1673.
@article{cb0b5cef52294385b016b5f1f693fa07,
title = "Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis",
abstract = "Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33{\%} over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. Introduction: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. Methods: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. Results: Over 4 years, risk of vertebral fracture was reduced by 33{\%} with strontium ranelate (risk reduction∈= ∈0.67, p∈",
keywords = "Bone densitometry, Menopause, Osteoporosis treatment, Osteoporotic fracture, Strontium ranelate",
author = "Meunier, {P. J.} and C. Roux and S. Ortolani and M. Diaz-Curiel and J. Compston and P. Marquis and C. Cormier and G. Isaia and J. Badurski and Wark, {J. D.} and J. Collette and Reginster, {J. Y.}",
year = "2009",
month = "10",
doi = "10.1007/s00198-008-0825-6",
language = "English",
volume = "20",
pages = "1663--1673",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "10",

}

TY - JOUR

T1 - Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis

AU - Meunier, P. J.

AU - Roux, C.

AU - Ortolani, S.

AU - Diaz-Curiel, M.

AU - Compston, J.

AU - Marquis, P.

AU - Cormier, C.

AU - Isaia, G.

AU - Badurski, J.

AU - Wark, J. D.

AU - Collette, J.

AU - Reginster, J. Y.

PY - 2009/10

Y1 - 2009/10

N2 - Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. Introduction: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. Methods: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. Results: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction∈= ∈0.67, p∈

AB - Vertebral fractures are a major adverse consequence of osteoporosis. In a large placebo-controlled trial in postmenopausal women with osteoporosis, strontium ranelate reduced vertebral fracture risk by 33% over 4 years, confirming the role of strontium ranelate as an effective long-term treatment in osteoporosis. Introduction: Osteoporotic vertebral fractures are associated with increased mortality, morbidity, and loss of quality-of-life (QoL). Strontium ranelate (2 g/day) was shown to prevent bone loss, increase bone strength, and reduce vertebral and peripheral fractures. The preplanned aim of this study was to evaluate long-term efficacy and safety of strontium ranelate. Methods: A total of 1,649 postmenopausal osteoporotic women were randomized to strontium ranelate or placebo for 4 years, followed by a 1-year treatment-switch period for half of the patients. Primary efficacy criterion was incidence of patients with new vertebral fractures over 4 years. Lumbar bone mineral density (BMD) and QoL were also evaluated. Results: Over 4 years, risk of vertebral fracture was reduced by 33% with strontium ranelate (risk reduction∈= ∈0.67, p∈

KW - Bone densitometry

KW - Menopause

KW - Osteoporosis treatment

KW - Osteoporotic fracture

KW - Strontium ranelate

UR - http://www.scopus.com/inward/record.url?scp=69949149543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=69949149543&partnerID=8YFLogxK

U2 - 10.1007/s00198-008-0825-6

DO - 10.1007/s00198-008-0825-6

M3 - Article

C2 - 19153678

AN - SCOPUS:69949149543

VL - 20

SP - 1663

EP - 1673

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 10

ER -